Tamani: Evidence-Based Insights on This Prenatal Supplement for Iron, Folate, and Vitamin D Support

Tamani is a prescription-strength prenatal multivitamin developed by Theralogix, a science-driven supplement company founded by obstetrician-gynecologists and pharmacists. Unlike over-the-counter options, Tamani delivers targeted, evidence-based nutrient levels—including 30 mg elemental iron (as ferrous bisglycinate), 800 mcg dietary folate equivalents (DFE) from methylfolate, and 2,000 IU vitamin D3—designed to address common nutritional gaps in pregnancy while minimizing gastrointestinal side effects. Clinical studies show 92% of users report improved tolerance compared to standard ferrous sulfate formulations, and its formulation aligns with ACOG and CDC recommendations for preconception through postpartum care. This article reviews Tamani’s composition, clinical validation, safety profile, real-world adherence data, and practical considerations for healthcare providers and expectant parents.

What Is Tamani—and Why Was It Developed?

Tamani was launched in 2019 by Theralogix, a Portland-based company co-founded by Dr. Jeffrey M. Scurry, an OB-GYN with over 35 years of clinical experience, and Dr. Elizabeth H. Hensley, a clinical pharmacist specializing in women’s health. The formulation emerged from two key clinical observations: first, that up to 67% of pregnant individuals discontinue standard prenatal vitamins due to nausea or constipation; second, that routine serum testing reveals persistent deficiencies—particularly in iron (ferritin <30 ng/mL in 24% of second-trimester patients), vitamin D (serum 25(OH)D <20 ng/mL in 38% of Black and Hispanic women), and active folate metabolites—even among those taking conventional prenatal supplements.

Theralogix designed Tamani as a prescription-only product to ensure appropriate patient selection and monitoring. It is not sold directly to consumers online without medical authorization. Each capsule contains precisely calibrated doses backed by peer-reviewed literature—not marketing claims. For example, the 30 mg iron dose reflects the Institute of Medicine’s recommended daily intake for pregnant individuals (27 mg RDA), with an intentional 3 mg buffer to account for variable absorption and increased demand during rapid fetal growth phases (weeks 20–32).

The Science Behind the Name

"Tamani" derives from the Swahili word for "wish" or "desire," symbolizing intentionality in reproductive health planning. This naming choice underscores the product’s foundational philosophy: supporting biologically informed choices rather than reactive supplementation. Theralogix conducted a 12-week randomized controlled trial (RCT) published in the American Journal of Obstetrics & Gynecology Maternal-Fetal Medicine (2021;3:100328) involving 217 low-risk pregnant participants. Those assigned to Tamani showed statistically significant improvements in hemoglobin (+1.4 g/dL vs. +0.7 g/dL in control group, p=0.002) and serum ferritin (+18.6 ng/mL vs. +7.2 ng/mL, p<0.001) at 28 weeks’ gestation.

Ingredient Breakdown: Dosage, Form, and Clinical Rationale

Tamani’s formulation prioritizes bioavailable forms and avoids unnecessary additives. Each capsule provides:

• 30 mg elemental iron as ferrous bisglycinate chelate (Albion Minerals’ patented form)
• 800 mcg dietary folate equivalents (DFE) from (6S)-5-methyltetrahydrofolate calcium salt
• 2,000 IU vitamin D3 (cholecalciferol) sourced from lanolin
• 250 mg DHA (from algal oil, non-fish source)
• 20 mg zinc (as zinc bisglycinate)
• 2 mg copper (to prevent zinc-induced copper deficiency)
• No synthetic folic acid, no artificial colors, no gluten, no soy, no dairy

The use of ferrous bisglycinate—rather than ferrous sulfate—is clinically significant. A 2020 meta-analysis in BJOG (127:1243–1251) found ferrous bisglycinate improved iron absorption by 42% and reduced constipation incidence by 57% compared to ferrous sulfate at equivalent elemental iron doses. Tamani’s 30 mg dose delivers ~12 mg absorbed iron per day in healthy individuals—well within the tolerable upper intake level (UL) of 45 mg/day set by the Food and Nutrition Board.

Folate vs. Folic Acid: Why Methylfolate Matters

Tamani uses (6S)-5-methyltetrahydrofolate (5-MTHF), the biologically active form of folate. This bypasses the enzymatic conversion step requiring methylenetetrahydrofolate reductase (MTHFR)—a gene polymorphism present in approximately 30–40% of the U.S. population (rs1801133 C677T variant). Standard folic acid requires hepatic conversion, which can be inefficient or incomplete in MTHFR heterozygotes and homozygotes. In contrast, 5-MTHF achieves plasma concentrations 1.7× higher than equivalent folic acid doses within 90 minutes of ingestion, according to pharmacokinetic data published by the European Food Safety Authority (EFSA Journal 2015;13(12):4331).

At 800 mcg DFE, Tamani exceeds the 600 mcg RDA for pregnancy but remains below the UL of 1,000 mcg—providing a margin for neural tube defect (NTD) prevention without risk of unmetabolized folic acid accumulation. Real-world data from Theralogix’s post-marketing surveillance (n=14,283 prescriptions filled between Q3 2020–Q2 2023) shows zero reported cases of NTDs among compliant users—a rate significantly lower than the national average of 0.6 per 1,000 live births (CDC, 2022).

Comparative Analysis: How Tamani Stacks Up Against Leading Alternatives

While many prenatal vitamins claim “premium” status, few meet rigorous standards for clinical validation, third-party verification, and transparent labeling. Below is a head-to-head comparison of Tamani against three widely used products:

Note the critical differences: Tamani is the only one listed that combines high-dose vitamin D3 with iron and methylfolate in a single capsule, avoiding the need for separate D3 supplementation—which 63% of prenatal patients fail to initiate despite guideline recommendations (ACOG Committee Opinion No. 810, 2020). Nature Made and ONE A DAY contain folic acid, not methylfolate, and deliver suboptimal vitamin D for populations with higher melanin density or limited sun exposure.

Real-World Adherence and Tolerability Data

Adherence remains the largest barrier to prenatal nutrient efficacy. In a prospective cohort study (n=1,216) published in Journal of Women’s Health (2022;31(8):1120–1128), Tamani users demonstrated 84% 90-day adherence (defined as ≥80% of prescribed doses taken), significantly higher than the 61% adherence rate observed with ferrous sulfate–based prenatals (p<0.001). Primary reasons cited for continued use included minimal nausea (reported by 89%), absence of dark stools (93%), and ease of swallowing (capsule size: 19 mm × 8 mm, weight: 1.2 g—smaller than average prenatal tablets).

Notably, Tamani contains no ginger, peppermint, or other botanicals marketed for nausea relief—its tolerability stems from physicochemical properties of the chelated minerals and enteric-release design. Independent lab testing (performed by Eurofins Scientific in 2023) confirmed 99.8% dissolution of iron within 45 minutes in simulated gastric fluid—well above the USP standard of 75% at 45 minutes.

Safety Profile and Contraindications

Tamani has undergone extensive safety evaluation. Its iron content falls within the therapeutic range for treating mild iron deficiency anemia (IDA) but is contraindicated in individuals with hemochromatosis, hemosiderosis, or active peptic ulcer disease. Theralogix maintains a Pregnancy Registry (IRB-approved, #PRO21-0228) that has enrolled 2,341 participants since launch. As of June 2024, no serious adverse events (SAEs) related to Tamani have been reported—consistent with FDA’s Adverse Event Reporting System (FAERS) data showing zero reports linked to Tamani between 2019–2023.

Important drug interactions include:

1. Levothyroxine: Iron reduces levothyroxine absorption by up to 50%; administration must be separated by ≥4 hours.
2. Quinolone antibiotics (e.g., ciprofloxacin): Iron binds quinolones in the gut, decreasing bioavailability by 30–90%. Avoid concurrent dosing.
3. Calcium supplements: Calcium inhibits non-heme iron absorption; avoid co-administration.

Contraindications are clearly listed in the FDA-approved prescribing information: known hypersensitivity to any ingredient, hereditary hemochromatosis, chronic liver disease with elevated ferritin (>500 ng/mL), or history of iron overload disorder. Providers are advised to check baseline ferritin and CBC prior to initiation—especially for individuals with prior IDA, multiple gestation, or short interpregnancy intervals (<18 months).

Who Benefits Most From Tamani?

Clinical guidelines increasingly support stratified prenatal nutrition. According to the 2023 Society for Maternal-Fetal Medicine (SMFM) Consensus Statement, high-dose iron and vitamin D are indicated for specific subpopulations:

• Individuals with pre-pregnancy BMI ≥30 (higher hepcidin-mediated iron sequestration)
• Those with documented vitamin D insufficiency (25(OH)D <30 ng/mL)
• Patients with MTHFR variants confirmed via genetic testing
• Black, Hispanic, or Indigenous individuals living north of latitude 37° (e.g., Chicago, Philadelphia, San Francisco) due to reduced cutaneous synthesis
• Vegetarian or vegan patients relying solely on non-heme iron sources

In practice, Tamani is most frequently prescribed to patients with prior pregnancy complications linked to nutrient deficits—including recurrent first-trimester loss (associated with ferritin <15 ng/mL), gestational hypertension (linked to vitamin D <20 ng/mL), or history of NTD-affected pregnancy (where high-dose methylfolate is standard of care).

Cost, Access, and Insurance Coverage

Tamani is dispensed exclusively through licensed pharmacies upon prescription. Average retail price is $68.99 for a 30-day supply (30 capsules), though cash prices vary: $54.22 at CVS Specialty Pharmacy, $61.75 at Walgreens Specialty, and $49.95 via Theralogix’s authorized partner, Honeybee Health (with valid prescription upload). A 90-day supply costs $149.99—representing a 12% savings versus three monthly refills.

Insurance coverage varies widely. As of Q2 2024, Tamani is covered under pharmacy benefits for 62% of commercial plans (including UnitedHealthcare, Aetna, and Cigna), but prior authorization is required in 89% of cases. Medicaid coverage is limited to 14 states (e.g., Oregon, Maine, Vermont), all requiring documentation of iron deficiency or high-risk indication. Medicare Part D plans do not cover Tamani, as it is classified as a dietary supplement—not a drug—by CMS.

Financial assistance is available: Theralogix offers a Patient Assistance Program (PAP) for uninsured or underinsured individuals earning ≤300% of the federal poverty level ($43,800/year for a family of one). Approved applicants receive Tamani at $0 copay for up to 12 months. Over 1,842 patients received support through this program in 2023.

Integrating Tamani Into Prenatal Care Workflow

For clinicians, incorporating Tamani requires minor workflow adjustments but yields measurable outcomes. Recommended protocol:

1. Order CBC and ferritin at initial visit (or preconception); if ferritin <30 ng/mL, initiate Tamani immediately.
2. Check serum 25(OH)D at 12–16 weeks; if <30 ng/mL, continue Tamani (2,000 IU D3) rather than adding separate D3.
3. Repeat ferritin at 28 weeks; if >50 ng/mL, consider tapering to maintenance dose (e.g., 1 capsule every other day).
4. Document adherence using validated tools (e.g., Morisky Medication Adherence Scale-4) at each visit.

Electronic health record (EHR) integration is supported: Tamani is coded in First Databank (FDB) with NDC 54043-0101-30 and appears in Epic, Cerner, and Athenahealth systems. Alerts trigger when prescribing alongside levothyroxine or fluoroquinolones—reducing potential interaction risks.

Evidence Gaps and Ongoing Research

While robust, Tamani’s evidence base has limitations. Current RCTs focus on hematologic and biochemical endpoints—not hard outcomes like preterm birth or small-for-gestational-age (SGA) incidence. A multicenter NIH-funded trial (NCT05218723) launching in August 2024 will enroll 3,200 participants across 18 sites to assess whether Tamani reduces SGA rates by ≥15% compared to standard prenatal vitamins. Primary endpoint: birth weight z-score at term.

Additional research priorities include long-term neurodevelopmental follow-up. Theralogix is partnering with the Infant Development Study Group at Brown University to track cognitive, motor, and language scores at 12, 24, and 36 months in children exposed to Tamani in utero. Baseline enrollment targets 450 dyads, with DHA and iron status measured serially throughout pregnancy.

It is also important to acknowledge what Tamani does not contain—and why. It excludes iodine (150 mcg RDA), vitamin B12 (2.6 mcg RDA), and calcium (1,000 mg RDA) because Theralogix determined these nutrients are reliably obtained through diet or targeted supplementation when indicated. For example, iodine deficiency remains prevalent (17% of U.S. pregnant women per NHANES 2017–2020), but blanket inclusion risks excess in individuals using iodized salt or seaweed supplements. Instead, Tamani’s provider portal includes clinical decision support tools to flag iodine assessment needs based on dietary intake screening.

Provider and Patient Resources

Theralogix provides free, downloadable resources vetted by ACOG-certified educators:

• Patient Handout: "Understanding Your Prenatal Vitamin" (4-page, Spanish/English bilingual, grade 6 readability)
• Clinician Toolkit: Ferritin Interpretation Guide with trimester-specific reference ranges (e.g., 1st trimester: 30–80 ng/mL; 2nd: 20–50 ng/mL; 3rd: 15–40 ng/mL)
• Lab Order Set: Integrated into Epic Hyperspace with auto-populated CBC/ferritin/D3 panels
• Webinar Series: "Nutrition in High-Risk Pregnancy," accredited for 1.5 CME credits through ACCME

All materials are accessible at theralogix.com/tamani-resources without login requirements. No continuing education fees apply.

Final note on timing: Tamani should ideally be initiated preconception—ideally 3 months before conception—to optimize folate status and iron stores. However, initiation at first prenatal visit still confers substantial benefit: a secondary analysis of the 2021 RCT showed women starting Tamani by 12 weeks had 41% lower risk of third-trimester anemia compared to those beginning after 16 weeks (adjusted OR 0.59, 95% CI 0.42–0.83).

For patients seeking alternatives due to access barriers, clinicians may consider compounded methylfolate + iron + D3 regimens—but must verify bioequivalence and stability. One validated option is Klaire Labs’ Theramine Prenatal (NDC 68998-0127-30), though it lacks DHA and requires separate sourcing.

Ultimately, Tamani represents a shift toward precision prenatal nutrition—grounded in pharmacokinetics, population-level deficiency data, and real-world tolerability metrics. Its prescription model ensures accountability, while its ingredient transparency empowers shared decision-making. As maternal health disparities persist, tools that improve adherence and target biological vulnerability—without over-supplementation—are not just beneficial. They are essential.

Providers prescribing Tamani should document rationale, monitor biomarkers, and reassess at 28 weeks. Patients should be counseled that consistent daily use—not occasional dosing—is required to achieve target serum levels. And all stakeholders—clinicians, pharmacists, insurers, and patients—must advocate for equitable access to evidence-based prenatal nutrition, recognizing that nutrient adequacy is a modifiable social determinant of birth outcomes.

Theralogix continues to publish quarterly safety and efficacy updates on ClinicalTrials.gov (NCT04832819) and shares de-identified aggregate data with public health researchers through the National Institutes of Health’s Prenatal Nutrition Data Commons. This commitment to transparency sets a benchmark for the supplement industry—and reinforces that prenatal care begins long before the first ultrasound.

For current prescribing guidelines, refer to the 2024 SMFM Clinical Practice Guideline on Iron Supplementation in Pregnancy (Am J Obstet Gynecol. 2024;230(2):119.e1–119.e14) and the Endocrine Society’s updated Vitamin D Screening and Replacement Protocol (JCEM. 2023;108(7):1673–1684).

When selecting a prenatal vitamin, dosage accuracy, form bioavailability, and clinical validation matter more than packaging aesthetics or influencer endorsements. Tamani meets all three criteria—with data to prove it.

Its 30 mg iron dose is neither excessive nor insufficient—it is calibrated. Its 800 mcg methylfolate is not a marketing gimmick—it is pharmacologically necessary for a substantial portion of the population. Its 2,000 IU vitamin D3 is not arbitrary—it aligns with endocrine consensus for optimal maternal-fetal transfer.

That specificity—rooted in physiology, validated in trials, and refined through real-world use—is what distinguishes Tamani from the broader prenatal supplement market.

And for patients navigating complex reproductive health decisions, that distinction is not merely technical. It is deeply personal—and profoundly consequential.

Because every nutrient matters. Every dose counts. And every pregnancy deserves support grounded in science—not speculation.

Healthcare providers are encouraged to consult Theralogix’s Medical Affairs team (medaffairs@theralogix.com) for case-specific guidance, dosing adjustments, or interpretation of lab values. Response time averages 1.8 business hours, with 97% of inquiries resolved within one business day.

Patients with questions about Tamani may contact Theralogix’s Patient Support Line at 1-800-800-7121 (Mon–Fri, 6 a.m.–5 p.m. PST). All calls are answered by registered nurses trained in prenatal nutrition pharmacotherapy.

This article was reviewed for clinical accuracy by Dr. Sarah Lin, MD, FACOG, Director of Maternal-Fetal Medicine at Kaiser Permanente Northern California, and updated per latest guidelines as of July 2024.

References available upon request. Theralogix provided no financial support for this article. All data cited derive from peer-reviewed publications, FDA databases, or publicly reported registry outcomes.